Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you that in continuation to our intimation dated 7th July, 2025, Company has received mandatory regulatory ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Veerhealth Care has received mandatory regulatory approval from the Food and Drug Authority, Gujarat to manufacture and supply personal care products for one of India's leading marketplace companies. Alongside this approval, the company has secured its first commercial order for skin care and face care products under contract manufacturing. The order is valued at Rs. 0.48 Crores and must be executed within 30 days. The client name is not disclosed due to confidentiality. More personal care products are expected to be added to the contract manufacturing portfolio going forward. The company expects this development to contribute positively to revenues.
Positively signals entry into private-label contract manufacturing for a major e-commerce/marketplace player, opening a potential growth avenue. However, the order size of Rs. 0.48 Cr is quite small, so the immediate stock impact may be limited unless it leads to larger follow-on orders.